

Calcium Channel Blocker (CCB) Amlodipine Besylate Therapy is Associated with Reduced Case Fatality Rate of COVID-19 Patients with Hypertension

Zhang LK, et al. Cell Discov. 2020 Dec 22; 6(1):96.

- Patients with comorbidity, such as hypertension suffer more severely with COVID-19 with elevated mortality.
- CCBs inhibits the post-entry replication events of SARS-CoV-2 *in vitro*, while no *in vitro* anti-SARS-CoV-2 effect was observed for angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs).
- Further, CCB combined with chloroquine showed a significantly enhanced anti-SARS-CoV-2 efficacy.
- A retrospective clinical investigation on hospitalized COVID-19 patients with hypertension as the only co-morbidity revealed that the amlodipine besylate therapy was associated with a decreased case fatality rate.

The results from this study suggest that Amlodipine administration to COVID-19 patients with hypertension as the co-morbidity might improve the disease outcome.